Lab901 has appointed Seegene as its exclusive diagnostics distributor for the ScreenTape system in the Korean market
The parties will also co-market their ScreenTape and Seeplex products in the global multiplex PCR diagnostics market.
Richard Rowling, Lab901's director of sales and marketing said: "Lab901 is delighted to have secured this deal with Seegene.
"Combining Seegene's highly multiplexed PCR diagnostic kits with Lab901's simple and convenient automated analysis instrument will bring a great boost to both companies' global sales".
Joel Fearnley, co-founder and chief executive officer of Lab901, commented "We are very excited about working with Seegene.
"The combination of their excellent multi-pathogen PCR tests with the simplicity, speed and sample traceability of the ScreenTape system will be of real value to diagnostic microbiology and virology laboratories".
"We are delighted to be working with Lab901 and we believe that its ScreenTape system will offer our global customer base a higher level of automation and standardisation".
commented Jong-Yoon Chun, founder and chief executive officer of Seegene.
Seegene's Seeplex tests are based on a breakthrough multiplexing PCR technology capable of detecting multiple pathogens in a single tube.
Currently, Seeplex tests offer laboratories worldwide, simple, cost-effective and comprehensive screening for Sexually Transmitted Diseases (STDs), respiratory viruses', sepsis, human papillomavirus (HPV) and pneumonia.
